Advertisement
Screener

BIOATLA, INC. (BCAB) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

BioAtla, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • BioAtla, Inc. pe ratio for the quarter ending 2026-06-30 was -0.21, a change of 0.17 year-over-year.
  • BioAtla, Inc. pe ratio for the quarter ending 2026-03-31 was -0.01, a change of 16.37 year-over-year.
  • BioAtla, Inc. pe ratio for the quarter ending 2025-12-31 was -0.01, a change of 24.59 year-over-year.
  • BioAtla, Inc. pe ratio for the quarter ending 2025-09-30 was -0.62, a change of 51.38 year-over-year.
  • BioAtla, Inc. pe ratio for fiscal 2026 was -0.21.
  • BioAtla, Inc. pe ratio for fiscal 2025 was -0.01, a change of 24.59 from fiscal 2024.
  • BioAtla, Inc. pe ratio for fiscal 2024 was -24.6, a change of 23.29 from fiscal 2023.
  • BioAtla, Inc. pe ratio for fiscal 2023 was -47.9, a change of 131.6 from fiscal 2022.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-0.21$6.73M-$31.45M
2026-03-31-0.01$271,180.60-$50.62M
2025-12-31-0.01$720,573.66-$59.61M
2025-09-30-0.62$40.35M-$64.71M
2025-06-30-0.39$23.04M-$59.52M
2025-03-31-16.38$1.01B-$61.88M
2024-12-31-24.6$1.72B-$69.78M
2024-09-30-52$4.25B-$81.82M
2024-06-30-31.66$3.31B-$104.56M
2024-03-31-69.39$8.27B-$119.24M
2023-12-31-47.9$5.91B-$123.46M
2023-09-30-32.82$4.07B-$124.08M
2023-06-30-61.53$7.17B-$116.53M
2023-03-31-58.2$6.38B-$109.69M
2022-12-31-179.5$19.11B-$106.48M
2022-09-30-136.82$14B-$102.33M
2022-06-30-51.56$5.13B-$99.48M
2022-03-31-88.88$8.97B-$100.96M
2021-12-31-368.3$35.14B-$95.4M
2021-09-30-585.93$51.8B-$88.41M
2021-06-30-888.04$68.48B-$77.11M
2021-03-31-1,544.48$81.78B-$52.95M
2020-12-31-1,525.89$54.71B-$35.85M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-0.21$6.73M-$31.45M
2025-12-31-0.01$720,573.66-$59.61M
2024-12-31-24.6$1.72B-$69.78M
2023-12-31-47.9$5.91B-$123.46M
2022-12-31-179.5$19.11B-$106.48M
2021-12-31-368.3$35.14B-$95.4M
2020-12-31-1,525.89$54.71B-$35.85M

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXOZYMES INC. (EXOZ)United States$0.058B
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Tevogen Inc. (TVGN)United States$0.049B
Instil Bio, Inc. (TIL)United States$0.048B-1.73
LeonaBio, Inc. (LONA)United States$0.047B-0.61
BioStem Technologies, Inc. (BSEM)United States$0.069B
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02